US regulators relax restrictions on rosiglitazoneBMJ 2013; 347 doi: http://dx.doi.org/10.1136/bmj.f7144 (Published 28 November 2013) Cite this as: BMJ 2013;347:f7144
- Michael McCarthy
The US Food and Drug Administration announced on 25 November that it is to lift most of its restrictions on GlaxoSmithKline’s antidiabetes drug rosiglitazone and would no longer limit its use to patients whose diabetes could not be controlled by other drugs.
Rosiglitazone (marketed as Avandia) was approved in the United States in 1999, but its safety came into question after a meta-analysis published in 2007 by the New England Journal of Medicine found a 43% increase in the incidence of myocardial infarction and a 64% increase in death from cardiovascular causes.1
However, another …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial